A A A

Psoriasis PDA References

All decision aids are based on best available clinical evidence.

References for the psoriasis patient decision aid include:

Campa M, Mansouri B, Warren R, Menter A. A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatology and therapy. 2016 Mar 1;6(1):1-2.

Canadian Psoriasis Guidelines Committee. Canadian Guidelines for the Management of Plaque Psoriasis. June 2009. Available from: http://www.dermatology.ca/media/guidelines/

Farahnik B, Beroukhim K, Zhu TH, Abrouk M, Nakamura M, Singh R, Lee K, Bhutani T, Koo J. Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials. Dermatology and therapy. 2016 Mar 1;6(1):25-37.

Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, Van Voorhees AS, Elmets CA,
Kaufman MB. Pharmaceutical Approval Update. Pharmacy and Therapeutics. 2016 Jun;41(6):355.
Leonardi CL, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008 May 31;58(5):851-64.

Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. . J Am Acad Dermatol. 2008 May 31;58(5):826-50.

Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. . J Am Acad Dermatol 2009 Apr;60:643-59.

Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. . J Am Acad Dermatol. 2009 Sep 30;61(3):451-85.

Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 5. Guidelines of care for the management and treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010;62:114-35.

Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Sammain A, Schlaeger M, Sebastian M, Sterry W. S3–Guidelines on the treatment of psoriasis vulgaris (English version). Update. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2012 Mar 1;10(s2):S1-s95.

Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI, Arenberger P, Bachelez H, Barker J, Dauden E, Jong EM. European S3‐Guidelines on the systemic treatment of psoriasis vulgaris–Update 2015–Short version–EDF in cooperation with EADV and IPC. Journal of the European Academy of Dermatology and Venereology. 2015 Dec 1;29(12):2277-94.

Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, Dubertret L. European S3‐Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology and Venereology. 2009 Oct 1;23(s2):1-70.

Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
British Journal of Dermatology. 2015 Dec 1;173(6):1387-99.

Product Information. Cosentyx (secukinumab). Novartis Pharmaceuticals, East Hanover, NJ.

Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.

Product Information. Taltz Autoinjector (ixekizumab). Eli Lilly and Company, Indianapolis, IN.

Ryoo JY, Yang HJ, Ji E, Yoo BK. Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis. Annals of Pharmacotherapy. 2016 May 1;50(5):341-51.

Smith N, Weymann A, Tausk FA, Gelfand JM. Complementary and alternative medicine for psoriasis: A qualitative review of the clinical trial literature. J Am Acad Dermatol. 2009 November; 61:841-56.
Tan J, Wolfe B. A patient decision aid for psoriasis based on current clinical practice guidelines. Archives of dermatology. 2012 Jun 1;148(6):718-23.

Youngson RM. Collins dictionary of Medicine fourth edition. 2005.